Last updated: May 17, 2026
The cost of sequencing a complete human genome has followed one of the most dramatic cost reduction curves in technological history. Understanding this trajectory helps explain why genome sequencing is now entering everyday healthcare.
The Human Genome Project: $3 Billion
The Human Genome Project was an international scientific collaboration launched in 1990 to sequence the first complete human genome. The project was completed in 2003 at a total cost of approximately $3 billion over 13 years. The result was a reference human genome – a complete sequence of the approximately 3 billion DNA base pairs in human DNA. This monumental achievement required the coordinated work of research institutions across multiple countries using the best technology available at the time.
Early 2000s: The Cost Curve Begins
In the early years after the Human Genome Project, sequencing one human genome still cost approximately $100 million. The technology was improving but remained exclusively in the domain of major research institutions. By 2007, the cost had dropped to roughly $1 million per genome. Sequencing the genome of James Watson (co-discoverer of DNA’s double helix structure) in 2007 cost approximately $1 million – still expensive but a landmark moment in personalized genomics.
Next-Generation Sequencing: The $1,000 Genome
The introduction of next-generation sequencing (NGS) technologies in the late 2000s caused the cost curve to steepen dramatically – faster than Moore’s Law for computer chips. By 2014, the cost had dropped below $1,000 per genome – a milestone that had been held as the threshold for clinical practicality. The Illumina HiSeq X system, introduced in 2014, could sequence human genomes at approximately $1,000 each at scale.
Current Costs: The Sub-$200 Genome
By 2023, the cost of clinical whole genome sequencing had dropped below $200 in many laboratory settings, and consumer-facing services offer whole genome sequencing starting at $199-$399 including basic reporting. Companies like Nebula Genomics (30x coverage WGS for $299) and Sequencing.com offer genuine whole genome sequencing at consumer prices. The cost continues to decline as technology improves.
Why the Cost Dropped So Fast
Several factors drove the extraordinary cost reduction: better chemistry that requires less reagent per sequencing run, automation that reduced labor costs dramatically, parallelization allowing millions of DNA fragments to be sequenced simultaneously, competitive pressure among sequencing technology companies (primarily Illumina vs. emerging competitors), and increasing software sophistication that made analysis faster and cheaper.
Where Costs Are Heading
Industry projections suggest whole genome sequencing costs will continue declining toward $100 and eventually lower. Several companies are pursuing the $100 genome milestone. Third-generation long-read sequencing technologies (from Pacific Biosciences and Oxford Nanopore) offer different tradeoffs and may eventually achieve clinical-grade quality at low cost. The $1 genome is considered theoretically achievable in the coming decades.
See current DNA testing options and pricing with our DNA Test Comparison tool.
What Today’s Genome Sequencing Actually Costs
By the mid-2020s, the raw sequencing cost for a human genome at clinical-grade coverage had dropped below $300 at major genomic service providers, with some high-throughput research facilities reporting internal costs under $200. Consumer whole genome sequencing services including Nebula Genomics, Dante Labs, and Sequencing.com offer 30x whole genome sequencing to consumers for prices ranging from $200 to $600 depending on the service tier and depth of coverage. Clinical whole genome sequencing at hospitals and reference laboratories, which includes physician ordering, sample handling, bioinformatics processing, variant interpretation, and a clinical report, typically costs $1,000 to $5,000 and is increasingly covered by insurance for appropriate clinical indications.
What the Cost Includes and What It Excludes
The dramatic cost figures publicized for genome sequencing typically refer to the raw sequencing cost only, the laboratory process of reading DNA base pairs. This does not include the substantial cost of everything that comes after raw sequencing: bioinformatics processing to assemble and align reads, variant calling to identify differences from the reference genome, filtering and prioritization of variants, annotation with clinical databases, physician review and interpretation, and the generation of a clinically actionable report. When all these components are included, the cost of a clinically useful whole genome sequencing result is substantially higher than the raw sequencing cost alone. Understanding this distinction helps consumers evaluate what they are actually getting when comparing different sequencing services at different price points.
Insurance Coverage of Genome Sequencing
Insurance coverage for genome sequencing has expanded substantially. Medicare and many commercial insurers now cover whole exome or whole genome sequencing for specific clinical indications, most notably for undiagnosed rare disease in children, for cancer diagnosis and treatment selection, and for certain inherited conditions. Pre-authorization requirements and medical necessity criteria vary by plan. The trend is clearly toward broader coverage as clinical evidence demonstrating diagnostic yield and health outcome improvements accumulates. For clinical whole genome sequencing, patients should work with their physician to document the clinical indication clearly in the authorization request and to understand whether a clinical laboratory has favorable contracts with their insurance plan.
The Future Cost Trajectory
The cost of genome sequencing is expected to continue declining, though the pace of decline may slow as the technology matures and the remaining cost is increasingly attributable to interpretation, reporting, and clinical support rather than the sequencing chemistry itself. New technologies including long-read sequencing from Pacific Biosciences and Oxford Nanopore Technologies offer capabilities that short-read sequencing lacks, such as phasing variants, detecting structural variants, and resolving repetitive genomic regions, though currently at higher cost. As these technologies mature and compete with established short-read platforms, prices are expected to decline. The longer-term trajectory points toward a sub-$100 sequencing cost for the raw data, with the value shifting entirely to interpretation infrastructure.
What Falling Costs Mean for Healthcare
The practical implication of dramatically lower sequencing costs is that genome sequencing is transitioning from a last-resort diagnostic tool used only for the most complex cases to a routine component of clinical care for an expanding range of conditions. Neonatologists now use rapid whole genome sequencing in critically ill newborns as a first-line diagnostic tool in leading medical centers. Oncologists use tumor and germline sequencing as standard workup for most solid tumors. Population-level genomic screening programs, which would have been economically impossible at earlier price points, are now feasible and are being studied in large research initiatives including the NHS Genomics England program and the US All of Us Research Program. As costs continue to fall, genomics will increasingly be part of routine healthcare rather than a specialized service.
This content is for educational purposes only and does not constitute medical advice. Consult a licensed genetic counselor or healthcare provider for personalized guidance.